NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners ...

In response to the Australian government’s announcement of the Medical Research Commercialization Initiative, GBS is in the process of evaluating and preparing expressions of interests towards further ...

Bacteria which 1 in 10 pregnant women carry, and which can cause death or serious complications in their babies, could be targeted in a cost-effective way by a future vaccine – even if it costs the ...

Researchers have discovered how the bacteria Group B streptococcus (GBS) avoids detection by the immune system during pregnancy. The findings, reported in the journal mBio, could lead to the ...